CYNAPSUS THERAPEUTICS
Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. The company specializes in the fields of healthcare, biotechnology, pharmaceutical, and therapeutics. It was founded in 2004 and headquartered in Toronto, Ontario.
CYNAPSUS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2004-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.cynapsus.ca
Total Employee:
11+
Status:
Closed
Contact:
416-703-2449
Email Addresses:
[email protected]
Total Funding:
36.68 M USD
Technology used in webpage:
Apple Whitelist
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Employees Featured
Founder
Stock Details
Investors List
Aisling Capital
Aisling Capital investment in Venture Round - Cynapsus Therapeutics
Venrock
Venrock investment in Venture Round - Cynapsus Therapeutics
OrbiMed
OrbiMed investment in Venture Round - Cynapsus Therapeutics
Official Site Inspections
http://www.cynapsus.ca
- Host name: 172.67.163.173
- IP address: 172.67.163.173
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cynapsus Therapeutics"
Cynapsus Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number 416-703-2449; Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. The …See details»
Cynapsus Therapeutics
June 25, 2022 Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of …See details»
Cynapsus Therapeutics Inc Com N (CYNAD) Profile
See the company profile for Cynapsus Therapeutics Inc Com N (CYNAD) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Cynapsus Therapeutics
Ron Hosking. B.Comm., C.A., Director. Ron Hosking is a Chartered Accountant and currently the CFO at PlantForm Corporation. Ron was previously Vice President Finance & CFO of PreMD …See details»
www.cynapsus.ca
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12See details»
Cynapsus Therapeutics Announces Proposed Public Offering in the …
May 15, 2015 Cynapsus Therapeutics Inc. announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United …See details»
Cynapsus Therapeutics Announces 2016 Analyst and Investor
Jul 6, 2016 Cynapsus’ Phase 3 clinical program for APL-130277 plans to rely on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the company intends to submit …See details»
Cynapsus Therapeutics (CYNA) Presents at Rodman & Renshaw …
Sep 9, 2015 Cynapsus has initiated its phase 3 clinical program for APL-130277, and intends to submit a new drug application in 2016. For more information, visit the company’s website at …See details»
Cynapsus Therapeutics - Toronto - Nextdoor
Cynapsus Therapeutics in Toronto. Connect with neighbourhood businesses on Nextdoor.See details»
Cynapsus Therapeutics Reports Second Quarter 2016 Financial …
Aug 10, 2016 - Recent Positive Dose Titration Data from Pivotal Phase 3 Clinical Program - - On Track for New Drug Application Submission in the First Half of 2017 - TORONTO, Aug. 10, …See details»
Cynapsus Therapeutics Announces $1 Million Financing - Yahoo …
Mar 9, 2012 Cynapsus Therapeutics Announces $1 Million FinancingSee details»
Cynapsus Therapeutics Reports First Quarter 2016 Financial …
Focus on Advancement of Pivotal Phase 3 Clinical Program in 2016. TORONTO, May 11, 2022 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a …See details»
Cynapsus Therapeutics - Overdrive Design
Restoring movement with ease. DESCRIPTION Overdrive was commissioned to rebrand Cynapsus Therapeutics in 2010 including collateral and website. Overdrive was then engaged …See details»
Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's …
Oct 14, 2014 Cynapsus Therapeutics Inc. today announced that its APL-130277 for Parkinson's was recognized as one of the Top Ten Neurology Projects to Watch by a joint selection …See details»
Cynapsus Announces No Buccal Mucosal Irritation in FDA …
May 14, 2014 Cynapsus Therapeutics Inc. , a specialty pharmaceutical company, today announced no irritation was observed when testing the APL-130277 sublingual apomorphine …See details»
Cynapsus Therapeutics moves forward with trials for Parkinson’s ...
Aug 15, 2016 Cynapsus Therapeutics Inc (NASDAQ:CYNA, TSE:CTH) told investors it has received a positive opinion regarding the safety of its Phase 3 trial of a...See details»
Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the …
Jul 17, 2014 Cynapsus Therapeutics Inc. , a specialty pharmaceutical company focused on Parkinson's disease, today announced that following communication from the United States …See details»
Cynapsus Therapeutics
Financial Statements YE 2015 (Audited) Click here to download the Form 10-K Annual Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934, for the period ended …See details»
Congress on Parkinson's Disease and Positive Data Presentations …
Dec 8, 2015 of Cynapsus. "We are encouraged by the clinical profile demonstrated to-date and the possibility to offer a treatment alternative for patients who suffer with Parkinson's disease. …See details»
Government of Canada announces the organization to establish …
5 days ago Today, the Honourable Kamal Khera, Minister of Health, announced over $6.3 million in funding over five years for the Sinneave Family Foundation to establish and lead the new …See details»